BioBright
BioBright, a subsidiary of Dotmatics, operates in the scientific research intelligence space with its AI-native multimodal platform Luma.
Profile
Provides an AI-powered platform that connects lab instruments and scientific data to automate research workflows.
BioBright, a subsidiary of Dotmatics, operates in the scientific research intelligence space with its AI-native multimodal platform Luma. Originally an independent startup focused on lab data integration, BioBright was acquired by Dotmatics in 2021 to bolster its scientific workflow automation capabilities. The Luma platform specializes in adaptive R&D workflows, integrating with lab instruments and scientific software while applying AI to streamline data processing.
Its customer base spans pharmaceutical companies, biotech firms, and academic research institutions dealing with complex multimodal data. Financial specifics are not publicly disclosed post-acquisition, but Dotmatics' parent company Vela reported $295.9 million in Q2 2026 revenue across its portfolio, with Luma positioned as a growth driver in the research automation segment. The platform's recent focus on flow cytometry workflows demonstrates its applied approach - one pharma customer reported saving multiple weeks per project through automated data acquisition. Unlike generic AI tools, Luma maintains domain-specific adaptations for life sciences, though this specialization also limits its addressable market outside core research verticals.
Who buys this
- Pharmaceutical R&D teams
- Biotechnology researchers
- Academic research labs
- Contract research organizations
- Government research agencies
Strengths and what to watch
Strengths
- Deep integration with scientific instruments and lab data formats
- Domain-specific AI trained on biomedical research patterns
- Parent company Dotmatics provides established distribution in life sciences
Watch for
- Dependence on Dotmatics' corporate strategy post-acquisition
- Niche focus may limit expansion beyond life sciences
- Competition from broader lab informatics platforms like Benchling
Key Information
- Founded
- 2015
- Headquarters
- Boston, Massachusetts. Financials. Revenue
Frequently Asked Questions
What does BioBright's Luma platform do?
BioBright's Luma platform connects lab instruments and scientific data through AI to automate research workflows. Specializing in life sciences, it integrates with lab equipment and software while applying domain-specific AI to streamline data processing for pharmaceutical, biotech, and academic researchers. (47 words)
Who uses BioBright's scientific automation tools?
Primary users include pharmaceutical R&D teams, biotech researchers, academic labs, contract research organizations, and government agencies. The platform serves institutions handling complex multimodal data, with one pharma customer reporting weeks saved per project through automated data acquisition. (45 words)
How does BioBright fit with Dotmatics?
Acquired by Dotmatics in 2021, BioBright strengthens its parent company's scientific workflow automation offerings. As part of Dotmatics' portfolio under Vela, Luma contributes to the $295.9 million Q2 2026 revenue while maintaining specialized AI for life sciences research. (46 words)
What makes BioBright different from other lab AI tools?
Unlike generic AI platforms, Luma offers domain-specific adaptations for life sciences, with deep integration for lab instruments and biomedical data formats. Recent focus on flow cytometry workflows demonstrates its applied approach, though this specialization limits expansion beyond core research verticals. (48 words)
What are BioBright's main competitive advantages?
Key strengths include instrument integration capabilities, domain-trained AI for research patterns, and Dotmatics' established life sciences distribution. However, niche focus creates competition from broader platforms like Benchling while dependence on corporate strategy post-acquisition presents risks. (46 words)
How does BioBright help pharmaceutical researchers?
The platform automates data acquisition and processing for drug discovery workflows. Case studies show weeks saved per project through streamlined instrument connectivity and AI-powered analysis, particularly in specialized areas like flow cytometry data processing for clinical research. (44 words)
Sources
- biobright.com — Product capabilities and positioning
- investors.bio-techne.com — Financial context for parent company segment
- www.informationweek.com — Industry context on tech restructuring
- investors.omniab.com — Benchmark for life sciences tech financials